BNP Paribas Financial Markets Makes New Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

BNP Paribas Financial Markets purchased a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 104,001 shares of the company’s stock, valued at approximately $735,000. BNP Paribas Financial Markets owned approximately 0.17% of Health Catalyst as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wells Fargo & Company MN increased its holdings in Health Catalyst by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 39,355 shares of the company’s stock valued at $278,000 after acquiring an additional 8,451 shares in the last quarter. Impax Asset Management Group plc grew its position in shares of Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after purchasing an additional 195,525 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Health Catalyst during the 4th quarter worth approximately $2,044,000. Intech Investment Management LLC raised its position in shares of Health Catalyst by 59.7% during the 4th quarter. Intech Investment Management LLC now owns 28,386 shares of the company’s stock worth $201,000 after purchasing an additional 10,611 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Health Catalyst in the 4th quarter valued at approximately $110,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Price Performance

Health Catalyst stock opened at $3.65 on Friday. Health Catalyst, Inc. has a 1 year low of $3.56 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a 50 day moving average price of $4.09 and a 200 day moving average price of $5.70. The company has a market cap of $254.04 million, a price-to-earnings ratio of -2.70 and a beta of 1.56.

Insider Transactions at Health Catalyst

In other news, General Counsel Benjamin Landry sold 13,827 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. This trade represents a 7.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the transaction, the chief operating officer now owns 216,250 shares in the company, valued at $977,450. The trade was a 7.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 41,147 shares of company stock worth $182,284 in the last ninety days. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HCAT has been the subject of several recent research reports. Evercore ISI downgraded Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday, April 9th. Citigroup dropped their price objective on Health Catalyst from $7.00 to $6.50 and set a “buy” rating for the company in a research report on Friday, April 25th. Stephens cut their target price on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. KeyCorp decreased their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 16th. Finally, Canaccord Genuity Group cut their price objective on shares of Health Catalyst from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.